Defective Reverse Cholesterol Transport Polygenic Risk Score

Your body has a quiet janitorial system that pulls cholesterol out of your artery walls and sends it back to your liver for disposal. When that system runs slowly because of the genes you were born with, cholesterol may linger where it can do damage, even if your standard lipid panel looks reasonable.

This test reads your DNA to estimate how efficiently that cleanup system is wired. It is a one-time genetic measurement, fixed at birth, that can help add context to why some people with normal-looking cholesterol still develop heart disease and others do not.

What This Score Actually Reflects

A polygenic risk score (a number built by adding up the effects of many small DNA variants) for defective reverse cholesterol transport is not a protein, hormone, or metabolite floating in your blood. It is a calculated number, derived from your germline DNA, that summarizes inherited variation across genes involved in HDL particle function and the path cholesterol takes from your arteries back to your liver.

The pathway it represents, called reverse cholesterol transport (RCT), is the best-characterized way the body removes cholesterol from peripheral tissues, including the inside of artery walls. HDL particles act as the trucks, ferrying cholesterol back to the liver for excretion. Variants captured by this score touch on HDL particle remodeling, cholesterol storage in cells, and the conversion of cholesterol-loaded immune cells into the foam cells that build plaque. Worth knowing: large trials have shown that simply raising HDL cholesterol does not reliably reduce cardiovascular events, and the field has shifted toward HDL function (how well HDL actually accepts and clears cholesterol) rather than HDL concentration as the more meaningful target.

Because this is a research-stage measurement, there is no universal cutpoint that separates a normal from an abnormal result. What it gives you is a relative read on inherited susceptibility, a piece of context that does not move with diet, exercise, or medication.

Heart Disease and Stroke Risk

The strongest human evidence behind this kind of score comes from research on inherited low HDL cholesterol. In a Korean study of about 58,000 adults, people carrying a high-risk genetic profile across variants linked to reverse cholesterol transport had higher odds of having low HDL cholesterol. Those with low HDL in that cohort were also more likely to have had a myocardial infarction or stroke compared with people without low HDL. This is a single observational study in a nutrition-focused journal, so the finding is suggestive rather than definitive.

Broader genetic research on cardiovascular disease confirms that inherited lipid risk acts in a dose-dependent way: people with more risk variants tend to have more events. Polygenic risk scores for coronary artery disease, which overlap with some of the genes involved in cholesterol transport, are independently associated with future heart attacks even after accounting for standard risk factors like LDL, blood pressure, and smoking. An important caveat: most of this strong outcome evidence comes from CAD and LDL-C polygenic scores. The American Heart Association has specifically noted that HDL-cholesterol-based polygenic scores have limited prognostic utility for atherosclerotic cardiovascular disease prediction on their own, which is why a defective reverse cholesterol transport score is best treated as one piece of context rather than a stand-alone predictor.

Why a Normal Lipid Panel Is Not the Whole Story

A standard cholesterol panel measures what is in your blood today. It cannot tell you how efficiently your arteries are clearing cholesterol back to your liver. People with a high inherited risk for defective reverse cholesterol transport can have HDL numbers that look acceptable while their HDL particles may do a poorer job of the cleanup work. Polygenic scores try to fill that gap by capturing lifelong genetic predisposition rather than a single-day snapshot, though for HDL-related scores the link to hard cardiovascular outcomes is less established than it is for LDL or CAD scores.

In familial hypercholesterolemia studies, adding a polygenic risk score to the picture changed the read on cardiovascular risk substantially. People in higher tiers of polygenic score had greater cardiovascular event risk than those in lower tiers, even within the same monogenic diagnosis. People who carried both a monogenic familial hypercholesterolemia mutation and a high polygenic score had the highest premature cardiovascular disease risk of any group studied.

How Strong Is the Evidence, Really

This is where honesty matters. There is no internationally standardized cutpoint that defines a high or low score for defective reverse cholesterol transport specifically, and no large prospective cohort has yet tested this exact score against hard outcomes. The strongest evidence in this space comes from related polygenic work on LDL and coronary artery disease, which consistently shows that aggregating many small genetic effects gives a meaningful read on lifetime cardiovascular risk. HDL-based polygenic scores, the closest published analog to a defective reverse cholesterol transport score, have been flagged by the American Heart Association as having limited prognostic utility for cardiovascular outcomes on their own.

When polygenic scores for coronary artery disease have been added to standard risk calculators like SCORE2 or QRISK2, they have at most modestly improved the ability to identify people who go on to have events, with the C-index (a measure of how well a model separates people who get the disease from those who do not) changing by a small amount in large analyses. A 2022 JAMA Internal Medicine review concluded that adding polygenic risk scores to traditional risk scores does not appear to provide meaningful improvements in clinical decision-making for primary prevention populations. The benefit, where it exists, is real but incremental, not transformative on its own.

What a Higher or Lower Result Means for You

A higher score means you inherited more variants associated with a sluggish cholesterol cleanup system. It does not mean you will develop heart disease. It means your lifetime baseline risk may be shifted upward, and that earlier and more aggressive attention to the things you can change becomes more valuable, not less.

A lower score means you inherited fewer of these risk variants. It does not mean you are immune. Cardiovascular disease is shaped by many genes, dozens of lifestyle factors, and decades of exposure. A favorable genetic read may shift your baseline downward, but it does not replace standard prevention.

One-Time Result, Lifetime Use

This is a genetic test. Your result will not change. You do not need to retest it. The value comes from integrating it into decisions you make over years: how aggressively you manage your lipids, when you start thinking about apolipoprotein B or Lp(a), how seriously you take a borderline LDL reading at age 40, whether you talk to your siblings and children about their own testing.

What does need ongoing tracking is the downstream lipid and cardiovascular picture. No guideline currently sets a specific monitoring cadence based on this score, but a reasonable approach for someone with a high result is a full lipid panel including ApoB (apolipoprotein B, a count of the cholesterol-carrying particles that drive plaque) on a regular basis, with hs-CRP (high-sensitivity C-reactive protein, a marker of artery inflammation) and Lp(a) (lipoprotein little-a, an inherited cholesterol particle measured once) checked early. If your score is lower, periodic lipid monitoring is still reasonable, but the urgency of intervention thresholds may shift.

When Results Can Be Misleading

Genetic tests carry their own kind of confounders, different from the day-to-day issues that distort blood-based labs.

• Variant panel coverage: the assay only reads the specific DNA positions it is designed to read. A score in the average range does not rule out rare variants in HDL-related genes that the panel does not cover.
• Ancestry effects: the risk weight of each variant comes from research populations that may not match your own ancestry. Scores built primarily in European cohorts perform less well in people of African, East Asian, or admixed ancestry, and the absolute risk implied by a given percentile can shift across populations.
• Score versus disease: a high score reflects inherited tendency, not a current diagnosis. A percentile is not an absolute probability. Being in the 80th percentile does not mean you have an 80 percent chance of heart disease.
• Different from a clinical-grade lipid test: this score does not measure how your HDL is functioning today. It estimates the genetic blueprint behind that function.
• HDL-specific scores are research-grade: HDL-cholesterol polygenic scores have specifically been noted to have limited prognostic value for cardiovascular outcomes on their own, so this result is best read alongside CAD- and LDL-focused information rather than as a stand-alone predictor.

What to Do With a High Score

A high inherited risk for defective reverse cholesterol transport should pull your prevention thinking forward, not paralyze you. The practical pathway looks like this:

• Get a fuller lipid picture: order an ApoB and an Lp(a) if you have not already. ApoB counts the atherogenic particles that drive plaque, and Lp(a) is a separately inherited risk that often travels with adverse lipid genetics.
• Add inflammation context: an hs-CRP gives you a read on whether your artery walls are also inflamed, which may compound the genetic risk.
• Consider imaging earlier: a coronary artery calcium scan in your 40s, rather than your 50s, can show whether plaque is already forming. This is a reasonable individualized choice rather than a formal guideline recommendation.
• Talk to a lipidologist or preventive cardiologist: a high polygenic score combined with even modestly elevated ApoB or LDL may change the threshold for starting a statin, and these specialists are most current on how to weigh that.
• Inform biological family: siblings and children share much of your inherited risk. A conversation about their own testing is worth having.

What you do not need to do is panic. Post hoc analyses of statin trials show that the same lifestyle and pharmacologic tools that lower cardiovascular risk in the general population work for people with high polygenic risk for coronary artery disease, and in absolute terms they tend to deliver more benefit, because the baseline risk is higher to start with.